Skip to Main Content

The chief executive of biotech Athira Pharma has permanently left the company after papers she published as a graduate student were found to contain altered research. Leen Kawas was suspended in June, after STAT asked the Alzheimer’s research company to comment on the allegations, and Athira announced her resignation as president, chief executive, and member of the board of directors today.

Mark Litton, the company’s chief operating officer, will take Kawas’ place to lead Athira.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment